The writing committee felt it is best to keep this as a quality measure only for the time being until more data become available pertinent to this measure and its impact in real-world patients. ACC indicates American College of Cardiology; ACCF, American College of Cardiology Foundation; AHA, American Heart Association; EPHESUS, Eplerenone Post Acute Myocardial Infarction Heart Failure Efficacy and Survival Study; FDA, US Food and Drug Administration; GRACE, Global Registry of Acute Coronary Events; NSAIDs, nonsteroidal anti-inflammatory drugs; NSTE- ACS, non ST-segment elevation-acute coronary syndrome; NSTEMI, non ST-elevation myocardial infarction; PM, performance measure; PCI, percutaneous coronary intervention; PURSUIT, Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin; QM, quality measure; STEMI, ST-segment elevation myocardial infarction; TIA, transient ischemic attack; TIMI, Thrombolysis in Myocardial Infarction; VF, ventricular fibrillation; and VT, ventricular tachycardia. Table 6. Continued No. Care Setting Measure Title Rationale for Creating New Measure Rationale for Designating as a Quality Measure as Opposed to a Performance Measure (If Applicable) 10 especially important given that we have expanded the perfor- mance measure set to include a larger and more comprehen- sive set of 17 performance measures than previously adopted. Our writing committee acknowledges the importance of the Defect-Free Care measure and would like to evaluate its performance and impact in real world before considering it in the future. We also emphasize the importance of assess- ing the impact of compliance (or lack thereof) to some or all performance measures on short- and long-term clinical out- comes. Our writing committee also recognizes that all per- formance measures and quality measures are dynamic and can be revised or retired based on the emergence of scientific evidence and new guideline recommendations. 